Sameer Farouk Sait, MBBS

In my research, I explore the molecular drivers of brain tumors, with the goal of identifying new targets that can be used to develop innovative targeted therapies. My colleagues and I look at how using different anti-cancer drugs individually and in combination affects tumor growth and resistance to therapy, including the influence of immature cells called stem cells. We also study the use of radioimmunotherapy (radiation therapy given with immunotherapy to precisely target brain cancer cells while sparing nearby normal healthy tissues).

I work closely with the Brain Tumor Center, led by developmental biologist Luis Parada at the Sloan Kettering Institute, to conduct translational research to identify more effective combination treatments for children and adults with NF1 high-grade gliomas and MPNSTs. I am also a member of the Pediatric Translational Medicine Program. Our shared goal is to take findings from laboratory studies, translate them into early-phase clinical trials for young patients, and improve these patients’ quality of their care. I enjoy being able to conduct research at MSK, where there are excellent resources for investigators like myself, while caring for patients. It provides an opportunity to make a difference and improve the lives of these young patients.

Beyond these research endeavors, I also collaborate with the team in the MSK Kids Clinical Genetics Service and Pediatric Cancer Predisposition Screening Program. Here, patients and families benefit from genetic counseling and testing for cancer predisposition syndromes like NF1. We’re starting to perform more sophisticated molecular testing in patients, such as testing for DNA fragments shed in the blood (circulating cell-free DNA), to not only detect cancer but also to understand why some people develop cancer. This may eventually lead to prevention, earlier intervention, and cures. There are also many exciting developments and specific drug treatments that have recently emerged for people with these cancer predisposition syndromes.

What I find most gratifying about my work is being able to apply the scientific knowledge I’ve acquired, offer patients innovative and less toxic treatments when feasible, and see these efforts benefit my patients. I was attracted to the field of pediatric neuro-oncology because I felt like there was a lot of room to improve the treatment that we use to care for patients with these cancers, especially given how prevalent they are in this patient population. Brain tumors are the second most common form of cancer in children, after leukemia.

When I meet an adolescent or young adult with cancer, I individualize the experience for them and try to make them feel empowered. Just as each person’s cancer has different or distinctive genetic changes, every person I care for is also unique. Beyond personalized care, it is also important to me to give patients the opportunity to express their concerns and ask any questions that they may have so I can alleviate their anxieties.

Cancer care for this age group is sometimes fragmented. Whereas some patients receive care from MSK’s pediatric oncologists, others will work with our medical oncologists. We have a special program here at MSK to ensure that patients in this age group receive seamless care.